Experimental immune cell therapy for advanced breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new type of immune cell therapy that targets specific markers on breast cancer cells. It is designed for patients with advanced or relapsed breast cancer who have not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III or IV breast cancer, or your cancer has come back after treatment.
- You are between the ages of 18 and 75.
- At least 2 weeks have passed since your last chemotherapy, radiation, or steroid treatment, and any side effects have improved.
- A biopsy shows that your cancer cells have one of the target markers: GD2, CD44v6, or HER2.
- Your overall health is good, as measured by a standard scale (ECOG performance status 0 or 1).
- You have normal bone marrow, kidney, and liver function, and your blood oxygen level is at least 90%.
- You are not pregnant or breastfeeding, and you do not have HIV, active hepatitis B or C, or a serious infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether immune cells taken from your own tumor (called tumor-infiltrating lymphocytes) can be grown in a lab and given back to you to fight the cancer. It is for people with advanced breast cancer who have exhausted standard treatment options.
This study tests a special immune cell therapy (CAR-T cells) that targets a marker called PSMA found on some cancer cells. It is for patients whose cancer has not been stopped by standard treatments and who meet certain health and lab requirements.
This trial tests a new type of cell therapy called CAR-T cells that are designed to find and attack cancer cells that have a specific marker (GD2 or PSMA). It is for people whose cancer has not been controlled by standard treatment, and it aims to see if this therapy is safe and effective.
This trial tests a new type of cell therapy called CAR-T cells that are designed to recognize and attack tumors with specific markers (GD2 or CD70). It may be an option for patients whose cancer has not responded to standard treatments.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins (CD19 and CD70) on your cancer cells. It is for patients with B-cell cancers that didn't respond to previous treatments.
This trial tests a type of immune therapy called CAR-T cells to treat autoimmune diseases. The treatment targets B cells, which are part of the immune system that can attack your own body in autoimmune conditions.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.